BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jan 05, 2009
 |  BioCentury  |  Finance

Phase III & cash constrained

Phase III & cash constrained

Company 3Q08 oper loss 9/30/08 cash Years cash Lead program
Active Biotech (SSE:ACTI) (A) $9.0 $28.1 0.78 Anyara in Ph III for renal cancer; laquinimod, which is partnered with Teva (NASDAQ:TEVA), in Ph III for multiple sclerosis (MS)
Adherex (AMEX:ADH; TSX:AHX) $3.3 $7.9 0.60 Sodium thiosulfate in Ph III to prevent chemotherapy-related hearing loss

Read the full 469 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >